These journals include CEO influence and the pharmaceutical industry; but they may not be exclusive to that industry. Good luck:

Carmeli, A., Schaubroeck, J., & Tishler, A. (2011). How CEO empowering leadership shapes top management team processes: Implications for firm performance. The Leadership Quarterly, 22(2), 399-411.

Combs, J. G., Ketchen, D. J., Perryman, A. A., & Donahue, M. S. (2007). The moderating effect of CEO power on the board composition–firm performance relationship*. Journal of Management Studies, 44(8), 1299-1323.

Offstein, E. H., & Gnyawali, D. R. (2005). CEO compensation and firm competitive behavior: Empirical evidence from the US pharmaceutical industry. Journal of Engineering and Technology Management, 22(3), 201-225.

Khurana, R., & Nohria, N. (2000). The performance consequences of CEO turnover. Available at SSRN 219129.

Veliyath, R., & Bishop, J. W. (1995). Relationship between CEO compensation and firm performance: Empirical evidence of labor market norms. The International Journal of Organizational Analysis, 3(3), 268-283.

View famous Tylenol crisis where CEO leadership played a decisive role in protecting public, industry and company stakeholder interests:

http://www.ou.edu/deptcomm/dodjcc/groups/02C2/Johnson%20&%20Johnson.htm

Personally, I would like to refrain from making any comparative observation. However, the influence of CEO on the performance of pharmaceutical company is undeniable. Pharmaceutical industry is research oriented, where quality and innovation play key roles. CEO of such industry should be a person who is able to engage, develop and empower the human resources for development of new drug formulation, new drug delivery system, ensuring quality assurance & quality control, Implementing current good manufacturing practices ( CGMP ), compliance of  FDA regulations etc. CEO's influence in pharmaceutical industry is visible not only on the bottom line, but also in the company's performance in innovation, inclusiveness and sustainability.

Dear Jaharkanti,

Thank you for answering my question. Like in other industries the visibility of a CEO in relation to the internal stakeholders is very important to create alignment, motivation etc. But in my opinion of growing importance to the external stakeholders due to the increase of generics (homogeneity of market), increase of fraud, decrease of innovative concepts etc. But... besides investors and analysts, which stakeholder group might be of growing importance? Hope you will be able to help me further. thxx

Having worked for 30 years in the industry, I'd also like to add a word or caution about making such links. Long term performance in Pharma is highly dependent of R&D performance and the ability to successfully commercialise new products. Pharma CEOs are often in role for 3-7 years, but the clock speed of the industry is such that any change they make in R&D will only just be beginning to bear fruit towards the end of their tenure.  So drawing meaningful links is a challenge. 

More immediate links might be possible in areas like development in emerging markets, regulatory performance, corporate social responsibility.  Most firms now produce CSR reports, which might be. Useful source, but I'm not aware of any research using these as the basis.